General Comments at the IRIS April Bi-Monthly Meeting

Chuck Elkins, Consultant, Washington, DC April 23, 2014



My comments address these points:

- 1. Thanks to EPA for listening to stakeholders in December.
- 2. Are there additional improvements possible for Step 1 meetings to maximize Early Detection of Issues?
- 3. How can NCEA be as efficient as possible in increasing constructive interaction with stakeholders?
- 4. Whose meetings are these, anyway?



2.Early Detection of Issues

- An analogy: Medical doctors are rightly focused primarily on curing or treating disease.
 - However, early detection of disease can make curing the disease easier, hence improving the final outcome.
 - Therefore developing effective methods of early detection across a wide range of diseases is a key priority.
- NCEA has rightly been focused on "cures" (e.g., how to craft better assessments)
 - But developing a set of early detection methods across a wide range of possible issues should be a priority.
 - Some analysis is needed; not a casual matter.



How to develop early detection methods?

- Suggested joint analytical effort:
 - Develop a list of most important TYPES of issues where early detection can help prevent costly delays and re-work.
 - Examine what NCEA can do to trigger the early identification of issues.
- Progress is already being made in these Step 1 meetings; MORE IS POSSIBLE.



Early Detection of Issues at Step 1

1	
	Type of issue frequently raised in past by stakeholders
	1. Priority: Is assessment low priority?
	2. Enough to Proceed: Is there enough information?
	3. <u>Missing Study:</u> Literature review missed a study?
	4. <u>Excluded Study:</u> Did criteria exclude important study from evidence tables?
	5. <u>Significance of effect:</u> Effect questioned with regard to human health significance?



Early Detection of Issues at Step 1

Type of issue frequently raised in past by stakeholders	More types of issues frequently raised by stakeholders
1. Priority: Is assessment low priority?	6. <u>MOA:</u> Should assessment be significantly influenced by MOA?
2. <u>Enough to Proceed</u> : Is there enough information?	7. <u>Strengths and Weaknesses:</u> What factors of particular studies need to be weighed in assessment
3. <u>Missing Study:</u> Literature review missed a study?	8. <u>Key studies:</u> Has NCEA identified these? Should they, and are they correct?
4. <u>Excluded Study</u> : Did criteria exclude important study from evidence tables?	9. <u>Interpretation:</u> Other interpretation disagreements
5. <u>Significance of effect:</u> Effect questioned with regard to human health significance?	10. <u>Needed research:</u> Has gap-filling research been identified?

3. How Achieve more Efficient Communication with Stakeholders

One suggestion: Use the web more

- As we all gain experience, more and more of these preliminary discussions can take place interactively on the web, making these in-person meetings even more effective and efficient.
- Use the web to communicate with stakeholders, thereby reducing stakeholders' uncertainties and helping everyone get ready for "next steps" for each chemical.



What information would be useful for a chemical-specific webpage: Page 1

- 1. Name of chemical and Docket #
- 2. Page updated last on [date]
- 3. IRIS Assessment Manager: [contact info]
- 4. Status:

Date	Status
9/03/14	Example: Draft assessment released for public comment
	NOTE: Older entries should be retained here to show history



- 5. Next Expected Major Milestone [estimated calendar quarter if known]
- 6. Problem statement [why NCEA is giving this chemical assessment priority]
- 7. Health and other endpoints planned to be addressed in the assessment [e.g. cancer, neurotox, developmental, ecological]



- Significant non-routine scientific issues planned to be addressed in this assessment [e.g. "relevance of dermal exposure", "biological significance of thyroid hormone level changes."]
- Significant and possibly relevant on-going research known to NCEA [e.g. research identified in "stopping rule" research plan.]



- 10. Key past milestones [dates and links. For example, holding of problem formulation meeting.]
- 11. Key documents to date [with links]
 - Report from Problem Formulation Meeting
 - Literature Search and search criteria
 - Latest evidence tables (current as of [date])
 - Graphical display of studies



- 11. Key Documents—continued
 - Comments of Federal agencies on draft assessment (together with draft assessment)
 - Draft assessment and draft charge questions released for public comment
 - Public comments on draft assessment and charge questions.
 - Final charge questions and final draft assessment sent to peer review panel.



- 11. Key documents—continued
 - Report of the Peer Review Panel
 - Agency response to peer review and public comments.
 - Comments of Federal agencies on final draft assessment
 - Final assessment [link] and key findings of the assessment [cancer classification, unit risk, RfD, RfC, etc.]
- 12. Ability for stakeholder to be notified of changes on this specific webpage.



4. Whose Meetings are these, anyway?

- These bi-monthly meetings still have a "command and control" feel to them—a onesided EPA meeting.
 - Should it be just an EPA meeting? or
 - Should it be a JOINT EPA/stakeholder meeting?
- EPA obviously needs to bring considerable material to the table, but early detection of issues is a two-way street.....



Whose meeting?

- Could stakeholders play a larger role?
 - How about an agreement on what stakeholders need to bring to the table for a particular meeting?
 - Joint Agenda
 - Solicit/research issues and put them on agenda
 - Get rid of the 5 minute rule
 - Leave plenty of time for general issues
- A pre-meeting planning session makes sense for efficiency reasons.



Summary

- 1. Thanks for the progress being made.
- 2. More joint analysis is needed on methods of early detection of issues
- 3. The web offers opportunities for more and better communication
- 4. Let's make Step 1 meetings a joint affair.

